GT Medical Technologies and Theragenics Partner for Cesium-131 Distribution

GT Medical Technologies, Inc. (GT MedTech), a company focused on enhancing the lives of brain tumor patients, has formed a strategic distribution partnership with Theragenics Corporation (Theragenics), a global leader in minimally invasive brachytherapy. This partnership, announced on May 1, 2024, aims to increase physician access to Cesium-131 seeds, thus providing more flexibility for their brachytherapy procedural needs.

Theragenics will become the exclusive distributor of Cesium-131 brachytherapy seeds and carriers, which are used to treat various cancers, including prostate cancer. GT MedTech, the sole manufacturer of Cesium-131, will continue to concentrate on promoting its FDA-cleared GammaTile® therapy for operable brain tumors in the U.S.

Cesium-131 is an isotope commonly used in Low Dose Rate (LDR) brachytherapy. This radiation treatment involves implanting tiny radioactive seeds directly into or near a tumor, delivering a high dose of radiation to the cancer cells while minimizing damage to surrounding healthy tissues.

CEO of GT Medical Technologies, Per Langoe, expressed enthusiasm about the partnership with Theragenics, highlighting its potential to advance cancer care by ensuring continued access to Cesium-131 for clinicians and patients, thus addressing critical healthcare needs.

Michael Krachon, President of Theragenics Interventional, emphasized Theragenics’ dedication to brachytherapy, noting that the inclusion of Cesium-131 in their portfolio will allow them to better support the clinical needs of the brachytherapy community. He added that this partnership will enhance efforts to raise awareness of brachytherapy as a viable treatment option for men with prostate cancer.

GT MedTech, solely manufacturing Cesium-131, remains committed to expanding its use to improve cancer treatment. Simultaneously, the company is driving the evidence-based adoption of GammaTile, aiming to establish a new standard of care for operable brain tumors.

GT Medical Technologies was formed by a team of brain tumor specialists with the goal of improving the standard of care and enhancing the lives of brain tumor patients. GammaTile has been FDA-cleared as a treatment for newly diagnosed and recurrent malignant intracranial tumors. Since its U.S. market release in March 2020, GammaTile has been adopted by over 100 leading institutions, with more centers integrating the therapy monthly.

Theragenics Corporation offers innovative medical solutions that help shape better futures for patients. As pioneers in brachytherapy, they provide minimally invasive, radiation-based treatments for various cancers, trusted by clinicians worldwide. Theragenics designs and delivers a diverse portfolio of products, including vascular access and specialty needles, serving critical needs across interventional radiology, cardiology, and vascular surgery.

This strategic partnership between GT MedTech and Theragenics represents a significant step forward in expanding treatment options for cancer patients. Through this collaboration, the companies aim to improve access to effective brachytherapy treatments, ultimately enhancing patient outcomes across a range of malignancies.